Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$13.27+0.17 (+1.30%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Mesoblast cash
Cash and short-term investments held at the end of each period.
Mesoblast's cash was $102.91M at Jun 30, 2026. For fiscal 2026 it was $102.91M, down 36.3% from the year before. Over ten years it grew 2.4% a year on average. The highest annual figure on record is $161.55M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $102.91M | -36.3% |
| FY2025 | Jun 30, 2025 | $161.55M | +156.6% |
| FY2024 | Jun 30, 2024 | $62.96M | -11.7% |
| FY2023 | Jun 30, 2023 | $71.32M | +18.0% |
| FY2022 | Jun 30, 2022 | $60.45M | -55.8% |
| FY2021 | Jun 30, 2021 | $136.88M | +5.8% |
| FY2020 | Jun 30, 2020 | $129.33M | +156.5% |
| FY2019 | Jun 30, 2019 | $50.43M | +33.5% |
| FY2018 | Jun 30, 2018 | $37.76M | -17.5% |
| FY2017 | Jun 30, 2017 | $45.76M | -43.5% |
| FY2016 | Jun 30, 2016 | $80.94M | -26.9% |
| FY2015 | Jun 30, 2015 | $110.70M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $102.91M | +63.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $129.98M | +67.6% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $161.55M | +126.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $38.03M | -22.1% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $62.96M | -6.9% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $77.55M | -9.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $71.32M | +18.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $48.80M | -36.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $67.62M | -28.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $85.50M | -26.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $60.45M | -55.8% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $76.76M | -51.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $94.85M | +22.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $115.96M | +7.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $136.88M | +5.8% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $158.26M | +163.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $77.53M | -4.7% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $108.12M | +213.1% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $129.33M | +156.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $60.08M | -14.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $81.35M | +5.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $34.54M | -37.4% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $50.43M | +33.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $70.39M | +18.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $77.02M | +62.5% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $55.14M | +20.5% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $37.76M | -53.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $59.54M | -46.2% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $47.39M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $45.76M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $80.94M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $110.70M | – |
See a number that looks wrong?